Aventis Pharmaceuticals Inc.

Sanofi

John Ziqi Jiang

Shujaath Mehdi

Philip M Weintraub

Paul Robert Eastwood

Kwon Yon Musick

Neil Moorcroft

Sukanthini Thurairatnam

Jeffrey Stephen Sabol

Christopher Loren Vandeusen

Jack Roger Koehl

Suzanne C Aldous

Lan Mu

William R Ewing

Alfred P Spada

Christopher J Burns

Timothy Francis Gallagher

Wei He

Heinz W Pauls

Michael R Myers

Stephen M Condon

Stefan Peukert

Kent W Neuenschwander

Joseph M Karpinski

Barbara S Rauckman

Robert D Groneberg

Robert L Morris

Aiwen Li

Yong Mi Choi-Sledeski

Gregory Bernard Poli

Barbara Hanney

Jean-Francois Sabuco

Michael R Becker

Brian L Pedgrift

Liang Ma

Mark A Bobko

Sungtaek Lim

Roderick S Davis

Uwe Schwahn

David Stefany

Stanly John

Jinqi Lu

Wan F Lau

Harry Randall Munson

Grzegorz T Stoklosa

James R Pribish

Michael W Fennie

Christopher L Vandeusen

Paul R Eastwood

This invention is directed to a compound of formula (I): wherein R, R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine hydrazide compounds as PGDS inhibitors

This invention is directed to a compound of formula (I): wherein R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine amide compounds as PGDS inhibitors

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)

The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP)

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

The present invention relates to a series of substituted indole derivatives of the formula I: 

Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)

Growing community of inventors

Hillsborough, NJ, United States of America

John Ziqi Jiang